Rosetta Genomics and MD Anderson Sign Research Collaboration
Posted on: Monday, 9 June 2008, 09:01 CDT
Rosetta Genomics has announced a research collaboration with The University of Texas MD Anderson Cancer Center and the Kleberg Center for Molecular Markers to develop a microRNA-based diagnostic test to predict risk of disease recurrence in lung cancer patients who have undergone curative resection.
The goal of this collaboration is to develop a test that will enable physicians to distinguish between patients with high and low risk of recurrence to optimize treatment regimens.
Amir Avniel, president and CEO of Rosetta Genomics, said: "We believe that the experience we have in working with microRNA biomarkers, combined with MD Anderson's extensive experience in lung cancer research, makes this a strong collaboration which may have a significant impact on the way lung cancer patients are diagnosed and treated."
Source: Datamonitor
Related Articles
- Introgen's Intravenous Nanoparticle Gene Therapy Shows Activity in Stage IV Lung Cancer Patients
- Neurologists Recommend MRIs for Early Detection of Brain Metastases in Lung and Breast Cancer Patients, Due to High Effectiveness of Radiosurgery
- Mersey Doctors 'Giving Up on Lung Cancer Patients'
- AmpliMed Begins Patient Enrollment for Phase I Trial of Amplimexon(TM) Plus Docetaxel in Patients With Lung, Breast and Prostate Cancer
- Bronchial Colonization and Postoperative Respiratory Infections in Patients Undergoing Lung Cancer Surgery*
- Drug Extends Lung Cancer Patients' Survival
- Anti-Tumor Drug Extends Lung Cancer Patients' Lives
- Streamlined Treatment Plan for Lung Cancer Patients Set Out By Health Experts
- Streamlined Treatment for Lung Cancer Patients Demanded
- Palliative Treatment of Painful Disseminated Bone Metastases With ^Sup 186^Rhenium-HEDP in Patients With Lung Cancer
 |
 |
User Comments (0)
RSS Feeds